Qlaris Bio
Dedham, MA · Biotechnology · 10 employees
Qlaris is advancing QLS-111, a novel topical ocular therapy designed to lower intraocular pressure through a unique mechanism of action. Unlike current treatments, QLS-111 selectively targets episcleral venous pressure (EVP) and enhances outflow distal to the trabecular meshwork. This innovative approach may offer improved treatment options for conditions in which EVP is limited or pathological
Funding history
- Seed — $3.9M — Jun 2026
- Venture - Series Unknown — $5.6M — Nov 2025
- Venture - Series Unknown — $24.0M — Apr 2024
- Venture - Series Unknown — $8.2M — Aug 2019
Recent signals
- Jun 17, 2026: Raised $3.9M in Seed
- Mar 10, 2026: Qlaris Bio Appoints Fred Guerard as President and Chief Executive Officer
- Nov 17, 2025: Raised $5.6M in Venture - Series Unknown
- Apr 22, 2024: Raised $24.0M in Venture - Series Unknown
- Aug 28, 2019: Raised $8.2M in Venture - Series Unknown
See plans & pricing → Track Qlaris Bio’s funding, hiring, and signals — with verified contacts — on Fundz.